{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T04:16:05Z","timestamp":1744863365362},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","atherosclerosis-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.atherosclerosis.2017.12.009","type":"journal-article","created":{"date-parts":[[2017,12,7]],"date-time":"2017-12-07T14:22:00Z","timestamp":1512656520000},"page":"35-41","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Combined blockade of renin-angiotensin-aldosterone system reduced all-cause but not cardiovascular mortality in dialysis patients: A mediation analysis and systematic review"],"prefix":"10.1016","volume":"269","author":[{"given":"Shao-Min","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wan-Bing","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing-Qing","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei-Fei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-Feng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2017.12.009_bib1","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S0140-6736(13)60687-X","article-title":"Chronic kidney disease: global dimension and perspectives","volume":"382","author":"Jha","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2017.12.009_bib2","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(14)60155-0","article-title":"Chronic kidney disease and the ageing population","volume":"383","author":"Tonelli","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2017.12.009_bib3","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/S0140-6736(14)60384-6","article-title":"Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure","volume":"383","author":"Ortiz","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2017.12.009_bib4","doi-asserted-by":"crossref","first-page":"A7","DOI":"10.1053\/j.ajkd.2016.12.004","article-title":"US renal data system 2016 annual data report: epidemiology of kidney disease in the United States","volume":"69","author":"Saran","year":"2017","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.atherosclerosis.2017.12.009_bib5","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators","volume":"342","author":"Yusuf","year":"2000","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2017.12.009_bib6","doi-asserted-by":"crossref","first-page":"e424","DOI":"10.1097\/MD.0000000000000424","article-title":"Effects of Angiotensin converting enzyme inhibition or Angiotensin receptor blockade in dialysis patients: a nationwide data survey and propensity analysis","volume":"94","author":"Wu","year":"2015","journal-title":"Med. Baltim."},{"key":"10.1016\/j.atherosclerosis.2017.12.009_bib7","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2017.12.009_bib8","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Dahlof","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2017.12.009_bib9","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients","volume":"45","author":"K\/DOQI Workgroup","year":"2005","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.atherosclerosis.2017.12.009_bib10","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1053\/euhj.1999.1740","article-title":"Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure","volume":"21","author":"Roig","year":"2000","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2017.12.009_bib11","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/s11906-006-0060-5","article-title":"Aldosterone breakthrough during RAS blockade: a role for endothelins and their antagonists?","volume":"8","author":"Rossi","year":"2006","journal-title":"Curr. Hypertens. Rep."},{"key":"10.1016\/j.atherosclerosis.2017.12.009_bib12","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/ki.2011.228","article-title":"Combined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients","volume":"80","author":"Chan","year":"2011","journal-title":"Kidney Int."},{"key":"10.1016\/j.atherosclerosis.2017.12.009_bib13","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.jacc.2010.03.105","article-title":"Effects of telmisartan added to Angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial","volume":"56","author":"Cice","year":"2010","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2017.12.009_bib14","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1681\/ASN.2013030273","article-title":"Long-term effects of spironolactone in peritoneal dialysis patients","volume":"25","author":"Ito","year":"2014","journal-title":"J.\u00a0Am. Soc. Nephrol."},{"key":"10.1016\/j.atherosclerosis.2017.12.009_bib15","doi-asserted-by":"crossref","first-page":"f360","DOI":"10.1136\/bmj.f360","article-title":"Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials","volume":"346","author":"Makani","year":"2013","journal-title":"Bmj"},{"key":"10.1016\/j.atherosclerosis.2017.12.009_bib16","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/ajh\/hps038","article-title":"Efficacy and safety of combined vs. single renin-angiotensin-aldosterone system blockade in chronic kidney disease: a meta-analysis","volume":"26","author":"Susantitaphong","year":"2013","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.atherosclerosis.2017.12.009_bib17","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/eurjhf\/hft082","article-title":"Renin-angiotensin system blockade in heart failure patients on long-term haemodialysis in Taiwan","volume":"15","author":"Tang","year":"2013","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.atherosclerosis.2017.12.009_bib18","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/clc.20838","article-title":"Spironolactone use in heart failure patients with end-stage renal disease on hemodialysis: is it safe?","volume":"33","author":"Chua","year":"2010","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2017.12.009_bib19","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1093\/ndt\/gfl752","article-title":"No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients","volume":"22","author":"Han","year":"2007","journal-title":"Nephrol. Dial. Transpl."},{"key":"10.1016\/j.atherosclerosis.2017.12.009_bib20","doi-asserted-by":"crossref","first-page":"c242","DOI":"10.1159\/000224790","article-title":"Influence of dual blockade of the renin-angiotensin system on thirst in hemodialysis patients","volume":"112","author":"Masajtis-Zagajewska","year":"2009","journal-title":"Nephron Clin. Pract."},{"key":"10.1016\/j.atherosclerosis.2017.12.009_bib21","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/j.1542-4758.2011.00560.x","article-title":"Associations of endothelial dysfunction and arterial stiffness with intradialytic hypotension and hypertension","volume":"15","author":"Dubin","year":"2011","journal-title":"Hemodial. Int."},{"key":"10.1016\/j.atherosclerosis.2017.12.009_bib22","first-page":"105","article-title":"Arterial hypotension in dialysis","volume":"22","author":"Urena","year":"2001","journal-title":"Nephrologie"},{"key":"10.1016\/j.atherosclerosis.2017.12.009_bib23","first-page":"331","article-title":"Chronic hypotension in the dialysis patient","volume":"15","author":"Cases","year":"2002","journal-title":"J.\u00a0Nephrol."},{"key":"10.1016\/j.atherosclerosis.2017.12.009_bib24","unstructured":"J. Higgins, S.e. Green, Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011], The Cochrane Collaboration 2011. www.cochrane-handbook.org. (Accessed 28 June 2017)."},{"key":"10.1016\/j.atherosclerosis.2017.12.009_bib25","author":"Wells"},{"key":"10.1016\/j.atherosclerosis.2017.12.009_bib26","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (minors): development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J. Surg."},{"key":"10.1016\/j.atherosclerosis.2017.12.009_bib27","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1037\/0022-3514.51.6.1173","article-title":"The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations","volume":"51","author":"Baron","year":"1986","journal-title":"J.\u00a0Pers. Soc. Psychol."},{"key":"10.1016\/j.atherosclerosis.2017.12.009_bib28","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1023\/A:1026595011371","article-title":"Equivalence of the mediation, confounding and suppression effect","volume":"1","author":"MacKinnon","year":"2000","journal-title":"Prev. Sci."},{"key":"10.1016\/j.atherosclerosis.2017.12.009_bib29","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1037\/1082-989X.7.1.83","article-title":"A\u00a0comparison of methods to test mediation and other intervening variable effects","volume":"7","author":"MacKinnon","year":"2002","journal-title":"Psychol. Methods"},{"key":"10.1016\/j.atherosclerosis.2017.12.009_bib30","first-page":"507","article-title":"A\u00a0prospective double-blind randomized placebo-controlled clinical trial to evaluate the safety and efficacy of spironolactone in patients with advanced congestive heart failure on continuous ambulatory peritoneal dialysis","volume":"23","author":"Taheri","year":"2012","journal-title":"Saudi J. Kidney Dis. Transpl."},{"key":"10.1016\/j.atherosclerosis.2017.12.009_bib31","first-page":"392","article-title":"Spironolactone in chronic hemodialysis patients improves cardiac function","volume":"20","author":"Taheri","year":"2009","journal-title":"Saudi J. Kidney Dis. Transpl."},{"key":"10.1016\/j.atherosclerosis.2017.12.009_bib32","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s11255-012-0320-z","article-title":"The dual blockade of the renin-angiotensin system in hemodialysis patients requires decreased dialysate sodium concentration","volume":"45","author":"Zwiech","year":"2013","journal-title":"Int. Urol. Nephrol."},{"key":"10.1016\/j.atherosclerosis.2017.12.009_bib33","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/hr.2010.238","article-title":"Effects of aliskiren on blood pressure and the predictive biomarkers for cardiovascular disease in hemodialysis-dependent chronic kidney disease patients with hypertension","volume":"34","author":"Morishita","year":"2011","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.atherosclerosis.2017.12.009_bib34","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/ndt\/gfu265","article-title":"Molecular regulation of the renin-angiotensin system in haemodialysis patients","volume":"30","author":"Kovarik","year":"2015","journal-title":"Nephrol. Dial. Transpl."},{"key":"10.1016\/j.atherosclerosis.2017.12.009_bib35","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3317\/jraas.2004.001","article-title":"Blood pressure in haemodialysis patients: the importance of the relationship between the renin-angiotensin-aldosterone system, salt intake and extracellular volume","volume":"5","author":"Doulton","year":"2004","journal-title":"J.\u00a0Renin Angiotensin Aldosterone Syst."},{"key":"10.1016\/j.atherosclerosis.2017.12.009_bib36","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1681\/ASN.2011121208","article-title":"The crossroad of RAAS modulation, inflammation, and oxidative stress in dialysis patients: light at the end of the tunnel?","volume":"23","author":"Zaritsky","year":"2012","journal-title":"J.\u00a0Am. Soc. Nephrol."},{"key":"10.1016\/j.atherosclerosis.2017.12.009_bib37","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.jacc.2013.09.056","article-title":"Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients","volume":"63","author":"Matsumoto","year":"2014","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2017.12.009_bib38","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ahj.2011.05.004","article-title":"Angiotensin-converting enzyme inhibitors and cardiovascular outcomes in patients on maintenance hemodialysis","volume":"162","author":"Chang","year":"2011","journal-title":"Am. Heart J."},{"key":"10.1016\/j.atherosclerosis.2017.12.009_bib39","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0002-9343(03)00366-8","article-title":"Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States","volume":"115","author":"Agarwal","year":"2003","journal-title":"Am. J. Med."},{"key":"10.1016\/j.atherosclerosis.2017.12.009_bib40","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/ndt\/gfh614","article-title":"Orthostatic hypotension at the introductory phase of haemodialysis predicts all-cause mortality","volume":"20","author":"Sasaki","year":"2005","journal-title":"Nephrol. Dial. Transpl."},{"key":"10.1016\/j.atherosclerosis.2017.12.009_bib41","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.2215\/CJN.02680314","article-title":"Intradialytic hypotension and risk of cardiovascular disease","volume":"9","author":"Stefansson","year":"2014","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.atherosclerosis.2017.12.009_bib42","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0272-6386(99)70188-5","article-title":"Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients","volume":"33","author":"Port","year":"1999","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.atherosclerosis.2017.12.009_bib43","first-page":"561","article-title":"U\" curve association of blood pressure and mortality in hemodialysis patients","volume":"54","author":"Zager","year":"1998","journal-title":"Med. Dir. Dial. Clin. Inc, Kidney Int"},{"key":"10.1016\/j.atherosclerosis.2017.12.009_bib44","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1161\/HYPERTENSIONAHA.108.125252","article-title":"Mechanisms of impaired potassium handling with dual renin-angiotensin-aldosterone blockade in chronic kidney disease","volume":"53","author":"Preston","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.atherosclerosis.2017.12.009_bib45","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the american college of cardiology foundation\/american heart association task force on practice guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2017.12.009_bib46","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/AC.68.1.2959632","article-title":"Survival and heart failure therapy in chronic dialysis patients with heart failure and reduced left ventricular ejection fraction: an observational retrospective study","volume":"68","author":"Derthoo","year":"2013","journal-title":"Acta Cardiol."},{"key":"10.1016\/j.atherosclerosis.2017.12.009_bib47","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1681\/ASN.V12122759","article-title":"Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study","volume":"12","author":"London","year":"2001","journal-title":"J.\u00a0Am. Soc. Nephrol."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915017314284?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915017314284?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T01:14:05Z","timestamp":1660094045000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915017314284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":47,"alternative-id":["S0021915017314284"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.12.009","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combined blockade of renin-angiotensin-aldosterone system reduced all-cause but not cardiovascular mortality in dialysis patients: A mediation analysis and systematic review","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.12.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}